Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

The two market leaders are targeting new obesity alternatives in their pipelines with an eye toward a triple threat.

Under terms of the license agreement, Novo Nordisk will acquire the rights to develop and commercialize UBT251 outside of ...

Novo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug ...

Novo Nordisk has said will be gaining exclusive worldwide rights to United Laboratories International’s investigational ...

Co., Ltd. have entered into an exclusive license agreement for UBT251 for the treatment of obesity, type 2 diabetes, and other diseases.

Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved 24% weight reduction at 48 weeks in a ...

Novo Nordisk already has a fairly well-stocked pipeline of candidates, but one of its near-term hopes – CagriSema, which ...

Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so-called "triple-G ...

Novo Nordisk is expanding its prospects in ... William Blair analysts noted that the pharma giant discontinued development of a triple agonist for chronic weight management in 2020 due to the ...

The issuer is solely responsible for the content of this announcement.

Novo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal worth up to $2bn as the Wegovy (semalgutide) developer ...